Biogen Idec also has the option to acquire the Massachusetts-based startup, which is developing a treatment for neurologic diseases.
US-based biopharmaceutical company Ataxion has raised $17m in a series A round funded by biotechnology company Biogen Idec and venture capital firm Atlas Venture.
Ataxion is a discovery-stage developer of therapies for neurological diseases. Its lead programme, acquired from Denmark-based biotech company Saniona in July 2013, concentrates on a group of genetic disorders called ataxias that cause dysfunction or degeneration of the cerebellum, the brain’s coordination centre.
In addition to its equity investment, Biogen Idec will also provide additional funding…
